ALLMedicine™ Hypertrophic Cardiomyopathy Center

May 7th, 2021 - Hypertrophic cardiomyopathy (HCM) is a complex heterogeneous cardiovascular disorder characterized by hypertrophied and disorganized myocytes with varying degrees of interstitial fibrosis. The current management strategies include genetic and fami...

May 3rd, 2021 - Hypertrophic Cardiomyopathy: A Species-Spanning Pathology.|2021|Horowitz BN,|

May 1st, 2021 - LV apical aneurysm in HCM: Implant ICD and anticoagulate?: Editorial comment on: "Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis."|2021|Kampaktsis PN,Tzoumas A,|

Apr 30th, 2021 - Hypertrophic cardiomyopathy (HCM) is characterized by multiple pathological features including myocyte hypertrophy, myocyte disarray, and interstitial fibrosis. This study sought to correlate myocardial histopathology with clinical characteristics...

Apr 30th, 2021 - Evaluating Histopathology to Improve Our Understanding of Hypertrophic Cardiomyopathy.|2021|Rowin EJ,Fifer MA,|

Apr 30th, 2021 - 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.|2021| ,Ommen SR,Mital S...

Mar 2nd, 2021 - Nonischemic cardiomyopathies encompass a broad spectrum of myocardial disorders with mechanical or electrical dysfunction without evidence of ischemia. There are five broad variants of nonischemic cardiomyopathies; hypertrophic cardiomyopathy (Var...

Nov 24th, 2020 - 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.|2020|Ommen SR,Mital S,B...

Nov 24th, 2020 - This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting d...

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

May 7th, 2021 - Hypertrophic cardiomyopathy (HCM) is a complex heterogeneous cardiovascular disorder characterized by hypertrophied and disorganized myocytes with varying degrees of interstitial fibrosis. The current management strategies include genetic and fami...

May 3rd, 2021 - Hypertrophic Cardiomyopathy: A Species-Spanning Pathology.|2021|Horowitz BN,|

May 1st, 2021 - LV apical aneurysm in HCM: Implant ICD and anticoagulate?: Editorial comment on: "Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis."|2021|Kampaktsis PN,Tzoumas A,|

Apr 30th, 2021 - Hypertrophic cardiomyopathy (HCM) is characterized by multiple pathological features including myocyte hypertrophy, myocyte disarray, and interstitial fibrosis. This study sought to correlate myocardial histopathology with clinical characteristics...

Apr 30th, 2021 - Evaluating Histopathology to Improve Our Understanding of Hypertrophic Cardiomyopathy.|2021|Rowin EJ,Fifer MA,|

Nov 19th, 2020 - Greater involvement of the patient and family in decision-making, clarity on the role of genetic testing and parameters for team-oriented care, and use of high-volume specialty centers are cornerstones of the first update in almost a decade of the...

Oct 14th, 2020 - Among the landmark presentations at the recent European Society of Cardiology virtual congress was the presentation on the EXPLORER-HCM randomized controlled trial. In this study, simultaneously published in The Lancet, the investigational drug ma...

Oct 14th, 2020 - Among the landmark presentations at the recent European Society of Cardiology virtual congress was the presentation on the EXPLORER-HCM randomized controlled trial. In this study, simultaneously published in The Lancet, the investigational drug ma...

Aug 28th, 2020 - An investigational drug that targets part of the molecular machinery underlying obstructive hypertrophic cardiomyopathy (HCM) can improve both symptoms and functional status in patients with the genetic disorder, suggests a placebo-controlled phas...

Aug 28th, 2020 - An investigational drug that targets part of the molecular machinery underlying obstructive hypertrophic cardiomyopathy (HCM) can improve both symptoms and functional status in patients with the genetic disorder, suggests a placebo-controlled phas...